Market Place
Sourcing Support
Akili Announces FDA Authorization Of EndeavorOTC For ADHD Treatment
18 Jun 2024 //
BUSINESSWIRE
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
14 May 2024 //
BUSINESSWIRE
Akili Amends Shionogi Deal, Shifts Strategy, Sets Q1 Results Date
30 Apr 2024 //
BUSINESSWIRE
Akili Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
BUSINESSWIRE
Akili Announces Positive Results from Shionogi’s Phase 3 Trial of EndeavorRx
27 Feb 2024 //
BUSINESSWIRE
Akili Announces Results from Phase 3 Trial of Localized Version of EndeavorRx
26 Feb 2024 //
BUSINESSWIRE
Akili Announces Business Transformation, Focusing on Non-prescription Model
13 Sep 2023 //
BUSINESSWIRE
Akili releases non-prescription version of video game digital therapy
08 Jun 2023 //
ENDPTS
Akili aims for adults with over-the-counter video game treatment
08 Jun 2023 //
ENDPTS
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment
31 May 2023 //
BUSINESSWIRE
Akili cuts about 30% of staff in effort to be `extremely lean`
17 Jan 2023 //
ENDPTS
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
01 Dec 2022 //
BUSINESSWIRE
Akili to List on Nasdaq Following Successful Business Combination
19 Aug 2022 //
BUSINESSWIRE
Akili’s deal to go public via SPAC could close soon
18 Aug 2022 //
RAPS
Shionogi starts pivotal Japanese trial of Akili’s ADHD app
02 Aug 2022 //
PHARMAPHORUM
Study brings Akili`s ADHD digital therapeutic tech to lupus
15 Jul 2022 //
FIERCEBIOTECH
Akili Announces Public Company Board of Director Nominees
11 Jul 2022 //
BUSINESSWIRE
Akili taps new commercial chief for ADHD video game therapy
07 Jun 2022 //
ENDPTS
Akili Announces Veteran Life Sciences Exec. Matt Franklin as President and COO
06 Jun 2022 //
BUSINESSWIRE
PureTech Founded Entity Akili Integrates Partnership with Roblox
26 May 2022 //
BUSINESSWIRE
Akili to Publish Data on AKL-T03 in MDD w/ Antidepressants
12 Apr 2022 //
BUSINESSWIRE
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
04 Apr 2022 //
BUSINESSWIRE
Akili to Speak at SXSW 2022 on Making New Class of Disease-Modifying Digital Tx
10 Mar 2022 //
BUSINESSWIRE
Akili to Present at Cowen’s 42nd Annual Health Care Conference
07 Mar 2022 //
BUSINESSWIRE
EEG data shows enhancement of brain activity to attention function in ADHD
22 Feb 2022 //
PHARMABIZ
After heavy losses in new SEC filing, Akili details uncertain financial future
15 Feb 2022 //
ENDPTS
Akili Interactive to Become Publicly Traded with Suvretta Holdings Corp. I
26 Jan 2022 //
BUSINESSWIRE
Akili and Shionogi find the clinical game hard to play
29 Sep 2021 //
EVALUATE
Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
29 Sep 2021 //
BUSINESSWIRE
Akili adds inattention treatment to prescription game slate
17 Aug 2021 //
FIERCEBIOTECH
Akili launches first marketing for FDA-approved ADHD video game
25 Jun 2021 //
FIERCEPHARMA
Akili Secures $160 M in Financing; Poised to Deliver on the Promise of Digital
26 May 2021 //
BUSINESSWIRE
Akili snags $160M for prescription video game to treat ADHD
26 May 2021 //
FIERCEBIOTECH
Akili’s therapeutic video game will be tested as a for Covid ‘brain fog’
07 Apr 2021 //
STATNEWS
Akili presents more positive trial data for ADHD gaming therapy
29 Mar 2021 //
CLINICALTRIALSARENA
PureTech Founded Entity Akili Announces the Results of EndeavorRx™
26 Mar 2021 //
BUSINESSWIRE
Akili Announces Appointment of Chief Marketing Officer
07 Oct 2020 //
BUSINESSWIRE
Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD
15 Jun 2020 //
BUSINESSWIRE
Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Digital
25 Feb 2020 //
AKILIINTERACTIVE
Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results
24 Feb 2020 //
BUSINESSWIRE
PureTech unites operations in Boston`s Seaport in bid to boost R&D
20 Jun 2019 //
FIERCE PHARMA
